Overview

Why dormant cancer cells matter, how the section is organised, and what questions it helps answer

Dormancy matters because recurrence risk is not driven only by what is visible on a scan.

It is also driven by what survives treatment quietly.

That includes residual, micrometastatic, and slow-cycling disease that may stay controlled for a long time before reactivating.

Why this section exists

The older cancer model was often simple.

Find the lesion.

Kill the lesion.

Dormancy research adds a more useful question:

  • should the goal be to kill it now

  • keep it deeply dormant

  • wake it and then kill it

Inflammation, stress signalling, immune surveillance, and tissue niche biology all affect that decision.

Start here

The main practical takeaway

Dormancy science does not replace standard oncology.

It changes the quality of the questions.

It helps people ask whether a plan is trying to eradicate visible disease, manage recurrence risk, reduce reactivation triggers, or some combination of all three.

That is especially useful when disease is tiny, stable, hard to detect, or biologically ambiguous.

Key References

Novel Strategies to Combat Dormant Disseminated Tumor Cells https://pmc.ncbi.nlm.nih.gov/articles/PMC8111294/

Cancer cell dormancy: An update to 2025 https://bmrat.biomedpress.org/index.php/BMRAT/article/download/994/2044

Cellular Dormancy in Cancer: Mechanisms and Potential Targeting https://pmc.ncbi.nlm.nih.gov/articles/PMC10372609/

Targeting cancer cell dormancy https://pmc.ncbi.nlm.nih.gov/articles/PMC11038906/

Last updated

Was this helpful?